Form 8-K - Current report:
SEC Accession No. 0001104659-25-009673
Filing Date
2025-02-05
Accepted
2025-02-05 16:15:17
Documents
14
Period of Report
2025-01-30
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm255474d1_8k.htm   iXBRL 8-K 40699
  Complete submission text file 0001104659-25-009673.txt   294711

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA abbv-20250130.xsd EX-101.SCH 4501
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE abbv-20250130_def.xml EX-101.DEF 30265
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE abbv-20250130_lab.xml EX-101.LAB 40526
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE abbv-20250130_pre.xml EX-101.PRE 28469
17 EXTRACTED XBRL INSTANCE DOCUMENT tm255474d1_8k_htm.xml XML 11751
Mailing Address 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064
Business Address 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064 (847) 932-7900
AbbVie Inc. (Filer) CIK: 0001551152 (see all company filings)

EIN.: 320375147 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35565 | Film No.: 25593475
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)